Theranexus SA (ALTHX) - Net Assets
Based on the latest financial reports, Theranexus SA (ALTHX) has net assets worth €2.90 Million EUR (≈ $3.39 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€10.54 Million ≈ $12.33 Million USD) and total liabilities (€7.64 Million ≈ $8.94 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check ALTHX strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €2.90 Million |
| % of Total Assets | 27.51% |
| Annual Growth Rate | 5.64% |
| 5-Year Change | -71.5% |
| 10-Year Change | 3129.05% |
| Growth Volatility | 6529.81 |
Theranexus SA - Net Assets Trend (2015–2025)
This chart illustrates how Theranexus SA's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Theranexus SA (ALTHX) market capitalisation.
Annual Net Assets for Theranexus SA (2015–2025)
The table below shows the annual net assets of Theranexus SA from 2015 to 2025. Also explore Theranexus SA annual equity growth to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €2.90 Million ≈ $3.39 Million |
+275.11% |
| 2024-12-31 | €-1.66 Million ≈ $-1.94 Million |
-174.58% |
| 2023-12-31 | €2.22 Million ≈ $2.60 Million |
-61.22% |
| 2022-12-31 | €5.73 Million ≈ $6.70 Million |
-43.74% |
| 2021-12-31 | €10.18 Million ≈ $11.90 Million |
-0.98% |
| 2020-12-31 | €10.28 Million ≈ $12.02 Million |
+3.08% |
| 2019-12-31 | €9.98 Million ≈ $11.66 Million |
-25.61% |
| 2018-12-31 | €13.41 Million ≈ $15.68 Million |
-28.33% |
| 2017-12-31 | €18.71 Million ≈ $21.87 Million |
+20723.82% |
| 2016-12-31 | €89.85K ≈ $105.05K |
-94.64% |
| 2015-12-31 | €1.68 Million ≈ $1.96 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Theranexus SA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 478917600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | €137.97K | 6.95% |
| Other Components | €7.16 Million | 360.38% |
| Total Equity | €1.99 Million | 100.00% |
Theranexus SA Competitors by Market Cap
The table below lists competitors of Theranexus SA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sangsangin Industry Co. Ltd.
KQ:101000
|
$57.93 Million |
|
FORTE MINERALS CORP.
F:2OA
|
$57.96 Million |
|
Ma Kuang Healthcare Holding Ltd
TWO:4139
|
$57.97 Million |
|
Nordwest Handel AG
F:NWX
|
$58.01 Million |
|
Sam-A Pharm. Co. Ltd
KQ:009300
|
$57.91 Million |
|
MacroWell OMG Digital Entertainment Co Ltd
TWO:3687
|
$57.89 Million |
|
Shinih Enterprise Co Ltd
TW:9944
|
$57.89 Million |
|
Freightos Limited Ordinary shares
NASDAQ:CRGO
|
$57.89 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Theranexus SA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -1,656,913 to 1,985,493, a change of 3,642,406.
- Net loss of 3,001,558 reduced equity.
- New share issuances of 7,219,180 increased equity.
- Other comprehensive income decreased equity by 637,721.
- Other factors increased equity by 62,505.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-3.00 Million | -151.17% |
| Share Issuances | €7.22 Million | +363.6% |
| Other Comprehensive Income | €-637.72K | -32.12% |
| Other Changes | €62.51K | +3.15% |
| Total Change | €- | % |
Book Value vs Market Value Analysis
This analysis compares Theranexus SA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 23.77x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 1.82x to 23.77x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | €1.89 | €3.43 | x |
| 2016-12-31 | €0.10 | €3.43 | x |
| 2017-12-31 | €6.00 | €3.43 | x |
| 2018-12-31 | €4.13 | €3.43 | x |
| 2019-12-31 | €2.63 | €3.43 | x |
| 2020-12-31 | €2.15 | €3.43 | x |
| 2021-12-31 | €1.77 | €3.43 | x |
| 2022-12-31 | €1.07 | €3.43 | x |
| 2023-12-31 | €0.29 | €3.43 | x |
| 2024-12-31 | €-0.19 | €3.43 | x |
| 2025-12-31 | €0.14 | €3.43 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Theranexus SA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -151.17%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 5.31x
- Recent ROE (-151.17%) is above the historical average (-239.11%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | -30.93% | -92.39% | 0.21x | 1.63x | €-686.32K |
| 2016 | -1766.01% | -1752.11% | 0.03x | 32.06x | €-1.60 Million |
| 2017 | -11.30% | -1430.55% | 0.01x | 1.09x | €-3.99 Million |
| 2018 | -41.19% | -4778.40% | 0.01x | 1.46x | €-6.59 Million |
| 2019 | -59.14% | -989.58% | 0.04x | 1.63x | €-6.52 Million |
| 2020 | -54.99% | -1628.46% | 0.02x | 2.00x | €-5.67 Million |
| 2021 | -93.44% | -1353889.37% | 0.00x | 1.94x | €-9.02 Million |
| 2022 | -114.65% | -1582.80% | 0.03x | 2.10x | €-7.14 Million |
| 2023 | -307.35% | -2304.16% | 0.04x | 3.26x | €-7.05 Million |
| 2024 | 0.00% | -77.30% | 0.61x | 0.00x | €-1.60 Million |
| 2025 | -151.17% | 0.00% | 0.00x | 5.31x | €-3.20 Million |
Industry Comparison
This section compares Theranexus SA's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $49,850,913
- Average return on equity (ROE) among peers: -78.23%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Theranexus SA (ALTHX) | €2.90 Million | -30.93% | 2.63x | $57.91 Million |
| Abionyx Pharma SA (ABNX) | $6.16 Million | -125.64% | 1.26x | $75.31 Million |
| Abivax SA (ABVX) | $33.94 Million | -14.97% | 0.12x | $8.82 Billion |
| Adocia (ADOC) | $4.33 Million | -149.05% | 3.07x | $83.49 Million |
| Aelis Farma SA (AELIS) | $2.38 Million | -114.51% | 1.64x | $14.34 Million |
| Biophytis S.A. (ALBPS) | $-1.13 Million | 0.00% | 0.00x | $2.38 Million |
| Cellectis (ALCLS) | $450.27 Million | -17.48% | 0.11x | $111.42 Million |
| Advicenne (ALDVI) | $-5.15 Million | 0.00% | 0.00x | $14.73 Million |
| Genoway (ALGEN) | $7.89 Million | 7.25% | 1.50x | $31.09 Million |
| Integragen (ALINT) | $691.87K | -367.93% | 7.36x | $582.39K |
| Medesis Pharma SA (ALMDP) | $-876.00K | 0.00% | 0.00x | $1.80 Million |
About Theranexus SA
THX Pharma Société Anonyme, a biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders. It is involved in the development of Batten-1, an initial drug candidate currently under Phase ½ clinical study for Batten disease. The company was formerly known as Theranexus Société Anonyme and change its name to THX Pharma Société Anonym… Read more